Replies to post #93234 on Biotech Values

[exwannabe]

SPPI re Zev's 10x greater market.

The issue is that MDs are still afraid there is a real issue using it early, and you still have the irrational fears.

Yes, I still hope for modest growth. But it is still Eoquin (and perhaps that HDAC inhib I forget the name of).

Zev and Fusilev were supposed to keep the lights on.

[genisi]

Not to mention it [Zevalin] works better and is recommended over rituxan.

I've noticed that there are many ongoing clinical trials testing Zevalin in varying combinations and indications. I didn't see any head to head against Rituxan in 1st line like this study testing CHOP+Bexxar vs. CHOP+Rituxan in 1st line follicular NHL:

http://clinicaltrials.gov/ct2/show/NCT00006721

Seems to me that this kind of study might boost the use of these radio-labeled antibodies. Has SPPI talked about such study with Zevalin?